All GLG News Analyses Filed Under: Endocrinology

Bariatric Surgery works to treat diabetes in the short run, but it is expensive and dangerous.

Slight weight loss is demonstrated in a large observational study. This seems to support smaller studies. However, this is not a main advantage of Levemir.

Rebooting the immune system represents a new avenue to explore, but its very early in the process.

This study evaluated a large number of patients treated with Levemir.  When patients are started on insulin therapy, one side effect is frequently weight gain.  This study demonstrated that Levemir did not result in weight gain, but rather weight loss (small amount).

  Abbot’s FreeStyle Lite™ Blood Glucose Monitoring System is innovative and will slowly capture strong market share.

This form of combination is alrady on the market-extended release niacin and lovastatin. It has not taken the market by storm. If side effects remain, this preparation may suffer the same fate.

  Simcor will help people with cholestorol issues and it will likely capture much of the market for this topic unless managed health care has their own input.

There is little use of Kineret in diabetics.

Type 1 diabetes mellitus is caused by an autoimmune destruction of the pancreatic beta cells. The Macrogenics Protege Study is a Phase II/III clinical trial to study an experimental drug called hOKT3γ1 (Ala-Ala) or teplizumab, a CD3 monoclonal antibody that may protect the beta cells. Teplizumab may...

This article confirms what many of us had expected.  Enenatide works, as predicted, with a TZD with comparable reductions in A1c to other settings.  Many physicians had been previously using the combination "off label"  The study allowed the label to be modified to include the combination,...